Scroll Top
LNZ100 and LNZ101 Phase 3 Timing
LENZ Therapeutics provided Phase 3 timing and formulation guidance for LNZ100 and LNZ101. LNZ100 is a 1.75% Aceclidine based eye drop while LNZ101 is a 1.75% Aceclidine based eye drop with Brimonidine. Both use LENZ's proprietary preservative free vehicle matrix to maximize comfort, efficacy and bioavailability.

LENZ Therapeutics Provides Phase 3 Timing Guidance

LENZ Therapeutics provided Phase 3 timing and formulation guidance at the Academy and Eyecelerator meetings in November.

LENZ shared they expect to start their pivotal Phase 3 trial in 2Q 2022.  This trial will include 2 eye drop formulations for presbyopia.

LNZ100
1.75% Aceclidine

  • Optimal concentration for a pinhole effect
  • Minimal concern of induced myopia

LNZ101
1.75% Aceclidine + Brimonidine

  • Potential for increased duration
  • Added benefit of eye whitening

Both formulations use LENZ’s proprietary, preservative free vehicle matrix to maximize comfort, efficacy and bioavailability.

Frequently Asked Questions

Both LNZ100 and LNZ101 are aceclidine-based eye drops that use LENZ‘s proprietary & preservative-free vehicle matrix to increase comfort, efficacy, and bioavailability. ​​LNZ100 contains 1.75% Aceclidine while LNZ101 contains 1.75% Aceclidine with Brimonidine, added for increased duration.

Using LNZ100 & LNZ101 aceclidine-based eye drops can uniquely improve near vision

  • Research shoes aceclidine targets iris sphincter and avoids the ciliary muscle
  • Least risk of induced myopia and uniquely avoids a myopic shift
  • Potential for longest duration on the market
  • Safe history proven in Europe for glaucoma

As per LENZ Therapeutics, they expect to start LNZ100 and LNZ101 Phase 3 trials in 2022. The phase 3 trial will include 2 eye drop formulations for presbyopia.

LENZ Therapeutics is a late-stage clinical organization developing the best ophthalmic pharmaceutical products that can help people improve their eye vision caused due to presbyopia